Resources for Researchers
The National Emerging Infectious Diseases Laboratories (NEIDL) is part of a national network of secure facilities studying infectious diseases that are—or have the potential to become—major public health concerns
Biocontainment Laboratory: George Mason University National Center for Biodefense and Infectious Diseases
The George Mason University National Center for Biodefense and Infectious Diseases Biomedical Research Laboratory (BRL) is one of the NIAID-supported Biocontainment Laboratories. The RBL supports research programs in the National Center for Biodefense and Infectious Diseases focusing on host resp
The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.
The Tufts New England Regional Biosafety Laboratory (RBL) is one of the NIAID-supported Regional Biocontainment Laboratories.
The Tulane University Regional Biosafety Laboratory (RBL) at The Tulane National Primate Research Center is one of the NIAID-supported Biocontainment Laboratories.
The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories.
Biocontainment Laboratory: University of Missouri Regional Laboratory for Infectious Disease Research (LIDR)
The University of Missouri Laboratory for Infectious Disease Research (LIDR) is one of the NIAID-supported Biocontainment Laboratories.
As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms u
This service can be used to develop and perform a variety of analytical assays to assess the properties of drug substances and their formulations.
This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.
The National Institutes of Health (NIH) AIDS Reagent Program provides critical research reagents and resources to the scientific community. The ARP acquires, develops, and produces state-of-the-art reagents and provides these reagents at no cost to qualified investigators throughout the world.